- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Zealand Study Reveals Importance of Patient Attitudes Toward Biosimilars
Patients who research medical information online are likely to be more concerned about switching from originator products to biosimilars, according to the study.
A New Zealand study of patients with rheumatic conditions suggests that providers need to be mindful of patient attitudes toward biosimilars to prevent biased therapy choices and poor outcomes.
Patients who do online searching for medical information about biosimilars are liable to have exacerbated concerns about switching to biosimilars, according to the study, which examined patient attitudes toward these agents. The findings also indicated that women are more likely to have concerns about switching from originator drugs to biosimilars.
Among the findings:
- There was a positive correlation between adverse events experiences from the originator and adverse events anticipated from the biosimilar (P < .001.
- There was a positive association between perceptions of originator safety and the expectation that biosimilars are unsafe (P <.001).
- There was a significant negative association between the perceived effectiveness of the current originator and a preference for a biosimilar medicine (P <.001).
To read more about the findings, visit The Center for Biosimilars.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024
January 14th 2024Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
Read More
